NewAmsterdam Pharma Company N.V. (NAMSW)
- GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company d
- Simply Wall St.
NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)
NewAmsterdam Pharma ( NASDAQ:NAMS ) First Quarter 2024 Results Key Financial Results Net loss: US$93.8m (loss widened...
- GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 -- -- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City – -- Strong financial position; ending the quarter with $
